A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

Summary

The main objectives of the study were * to compare the pharmacokinetics (PK) of Optivate® and Haemate P® in various types of vonWillebrand disease (VWD) using the results from the VWF: RCo, VWF:Ag, VWF:CBA and Factor VIII assays. * to compare the clinical tolerance and safety of these two treatments after single IV infusions in subjects with VWD.

Timeline

Start

2004-12

Primary completion

2005-06

Completion

—

Drugs

Indications